title: Target hemoglobin in patients with renal failure.
abstract: 15 years after recombinant erythropoietin (EPO) has become available for the treatment of renal anemia, the target hemoglobin concentration to be achieved is still controversial. A positive impact of partial correction of renal anemia on quality of life has been conclusively demonstrated. Several more recent studies indicate that further improvement of well-being can be achieved with normalization of hemoglobin levels. In addition, there is increasing evidence that anemia is associated with the progression of left-ventricular hypertrophy and mortality. These findings imply that correction of renal anemia has the potential to improve patient prognosis. However, in patients with advanced cardiac disease, the US normal hematocrit failed to demonstrate a prognostic benefit and instead suggested that the attempt to normalize hemoglobin may be harmful. Nevertheless, in patients with less advanced cardiac disease complete correction of renal anemia may prevent progressive ventricular dilatation. The impact of early anemia correction is currently tested in several trials in predialysis patients. Irrespective of the uncertainties about the upper target range, current US and European guidelines have defined a hemoglobin concentration of 11 g/dl as the lower target range on the basis of both symptomatic and prognostic considerations. In the majority of patients these minimum requirements are not yet achieved. Less then 10% of patients receive EPO prior to the onset of dialysis, the mean hemoglobin level at the start of dialysis is not higher than 9 g/dl and a significant proportion of patients permanently remain below 11 g/dl.
authors.affiliation: Department of Nephrology and Medical Intensive Care, Charité, Campus Virchow-Klinikum, Berlin, Germany. kai-uwe.eckardt@charite.de
authors.forename: K U
authors.initials: KU
authors.lastname: Eckardt
mesh_terms: D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000401:mortality; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use*; D006454:Hemoglobins; D006801:Humans; D006973:Hypertension / Q000401:mortality / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000401:mortality / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000401:mortality / Q000503:physiopathology*
chemical_list: D006454:Hemoglobins; D004921:Erythropoietin